Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 11/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | NHERF1 | O14745 | 4/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23622980 | 0.91 | STING1 (0.48) | STING1KMT2ANHERF1TRPV1MEN1 | |
| SCHEMBL23623017 | 0.90 | STING1 (0.49) | STING1RAB9A | |
| SCHEMBL23622927 | 0.87 | STING1 (0.64) | STING1KMT2ATRPV1MEN1RAB9A | |
| SCHEMBL23622976 | 0.84 | STING1 (0.43) | STING1KMT2ARAB9A | |
| SCHEMBL23622979 | 0.83 | STING1 (0.46) | STING1KMT2ATRPV1MEN1RAB9A | |
| SCHEMBL23623037 | 0.80 | STING1 (0.62) | STING1TRPV1 | |
| SCHEMBL23625760 | 0.80 | STING1 (0.45) | STING1KMT2ATRPV1MEN1RAB9A | |
| SCHEMBL23623122 | 0.79 | STING1 (0.43) | STING1 | |
| SCHEMBL23625790 | 0.79 | STING1 (0.41) | STING1 | |
| SCHEMBL30385346 | 0.79 | STING1 (0.46) | STING1NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2021138434-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | STING1 1/4885KMT2A 3772/4885GRIK1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.